[
    [
        {
            "time": "",
            "original_text": "中信建投医药|行业周报】基金三季度持仓：重点领域龙头获得青睐",
            "features": {
                "keywords": [
                    "中信建投",
                    "医药",
                    "基金",
                    "三季度",
                    "持仓",
                    "重点领域",
                    "龙头"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "中信建投医药|行业周报】基金三季度持仓：重点领域龙头获得青睐",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "一周两单并购案被否 标的盈利能力存疑成“通病” 并购重组异常",
            "features": {
                "keywords": [
                    "并购案",
                    "被否",
                    "标的",
                    "盈利能力",
                    "存疑",
                    "通病",
                    "并购重组",
                    "异常"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "一周两单并购案被否 标的盈利能力存疑成“通病” 并购重组异常",
                "Correlation": 6,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]